May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Development of PLGA and PLLA microspheres of Ganciclovir for sustained ocular delivery in the treatment of Cytomegalovirus retinitis
Author Affiliations & Notes
  • S. Duvvuri
    Pharmaceutical Sciences, University of Missouri–kansas City, Kansas City, MO
  • A.K. Mitra
    Pharmaceutical Sciences, University of Missouri–kansas City, Kansas City, MO
  • Footnotes
    Commercial Relationships  S. Duvvuri, None; A.K. Mitra, None.
  • Footnotes
    Support  EY 09171–06 , EY 10659–05
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5065. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Duvvuri, A.K. Mitra; Development of PLGA and PLLA microspheres of Ganciclovir for sustained ocular delivery in the treatment of Cytomegalovirus retinitis . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5065.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : The purpose of this work was to develop the sustained release formulation consisting of biodegradable microspheres of GCV using poly (DL–lactide–co–glycolide) (PLGA) and poly (L–lactide ) (PLLA) for intraocular delivery of GCV. Methods: Microspheres were prepared by dispersing ganciclovir in PLGA and PLLA solutions in methylene chloride at room temperature that were further dispersed in 4% PVA solution. The resulting microspheres were filtered, washed and dried under vacuum for 12 hours. Particle size measurement, size distribution, encapsulation efficiency and in vitro release study were subsequently carried out. Release studies were carried out in isotonic phosphate buffer saline (pH 7.4) in a shaking water bath at 37 °C and 60 rpm. Results:Ganciclovir loaded microspheres were found to be spherical and of uniform particle size. Drug entrapment loading efficiencies of about 50 – 55 % were observed for both PLGA and PLLA microparticles. In the in vitro release studies, controlled release pattern was observed after an initial burst phase. Drug release was observed over a period of 3 – 4 weeks from both PLGA and PLLA microspheres. Conclusion:A new method for preparation of microspheres of Ganciclovir has been developed that requires minimal use of toxic solvents. High drug entrapment efficiencies were observed for both PLGA and PLLA polymers through the current method. These microspheres could result in sustained delivery of ganciclovir to the posterior segment of the eye following intravitreal administration in treatment of Cytomegalovirus retinitis.

Keywords: cytomegalovirus • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×